Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Coherus Oncology, Inc. (NASDAQ:CHRS)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.19 and traded as high as $1.40. Coherus Oncology shares last traded at $1.39, with a volume of 751,821 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CHRS shares. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a report on Wednesday, October 8th. Finally, Maxim Group raised Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Thursday, September 4th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.02.

Coherus Oncology Stock Performance

The business’s 50 day simple moving average is $1.46 and its two-hundred day simple moving average is $1.19. The firm has a market capitalization of $168.01 million, a PE ratio of 1.05 and a beta of 0.95. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42.

Coherus Oncology (NASDAQ:CHRS) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $13.41 million. Research analysts expect that Coherus Oncology, Inc. will post -1.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coherus Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in Coherus Oncology by 0.8% during the second quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company’s stock valued at $1,958,000 after buying an additional 20,976 shares during the period. UBS Group AG grew its position in shares of Coherus Oncology by 38.5% during the 3rd quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after acquiring an additional 221,410 shares during the period. Panagora Asset Management Inc. bought a new stake in shares of Coherus Oncology during the 2nd quarter valued at $581,000. Tejara Capital Ltd increased its stake in shares of Coherus Oncology by 1.7% in the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock worth $511,000 after purchasing an additional 11,552 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in Coherus Oncology by 148.2% in the 1st quarter. Stonepine Capital Management LLC now owns 620,588 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 370,588 shares during the period. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.